The increased expression, mutation, and activation of the HER family members, in particular EGFR and HER2, have been reported in a wide range of human cancers and have been associated with tumour progression, resistance to therapy, and ultimately, a poorer prognosis [16,33,34,35,36,37]. Here, ERBB2 is linked to neoplasm.